retatrutide clinical trial weight loss data Eli Lilly infiltrates anti-obesity market as Phase III for begins Lilly's retatrutide shows 28% weight

Both medicines are recommended for use within specialist weight management services (Tier 3 or Tier 4), and eligibility criteria apply including BMI thresholds and the presence of weight-related comorbidities

It helps address symptoms such as

Excess skin may show up around the belly area or even the face and can sometimes cause its own issues: This excess skin may feel uncomfortable, make clothes fit awkwardly, lead to irritation and even hygiene challenges

This has produced a physician workforce that is often unprepared to address poor dietthe leading risk factor for death and disability in the U.S

If nighttime dryness improves but daytime symptoms persist, add more frequent sipping intervals or a daytime oral spray

Expert consensus on managing GLP-1 gastrointestinal adverse effects supports smaller portions, avoiding overly fatty foods, and maintaining adequate fluid intake